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tDITORIAL COMMENT
he Metabolic Syndrome*
ichael Domanski, MD, FACC,†
ichael Proschan, PHD‡
ethesda, Maryland
he “metabolic syndrome” is a cluster of risk factors for
ardiovascular disease (CVD) that includes hypertension,
ypertriglyceridemia, low levels of high-density lipoprotein,
nsulin resistance, and obesity (1). Different diagnostic
riteria for this syndrome have been suggested (2,3). Re-
ently, the National Cholesterol Education Program
NCEP) put forth a definition that required the presence of
t least three of the following five criteria to make a
iagnosis: high-density lipoprotein 40 mg/dl in men or
50 mg/dl in women; blood pressure 130/80 mm Hg;
asting glucose 110 mg/dl; triglycerides 150 mg/dl; and
aist circumference 40 inches in men or 35 inches in
omen (2). An important feature of this recommendation is
hat each of the components is easily ascertainable.
See page 1388
The use of the NCEP definition results in an apparent
pidemic. The prevalence of metabolic syndrome in the
.S. population older than 20 years is 24% and rises to
40% in patients 60 years of age (1). The growth in
revalence of the metabolic syndrome parallels the dramatic
ise in the prevalence of obesity (4).
The grouping of known cardiovascular risk factors into a
yndrome has currency only if the components are syner-
istic in their effect and/or they have a common etiology.
lthough limited, available data suggest that the elements
f the syndrome interact in a way that worsens the prognosis
ore than would be expected from the simple addition of
isk factors.
The Botina study is a large (6,645 individuals) family
tudy conducted in Finland and Sweden that aims to
dentify early metabolic defects in families of type 2 diabet-
cs (5). Isomaa et al. (6) studied 4,483 of these participants,
ge 35 to 70 years, and identified those with metabolic
yndrome according to the definition of the World Health
rganization (WHO) (3). These criteria for diagnosis are
ifferent from those put forth by the NCEP, most impor-
antly in incorporating microalbuminuria and a measure of
nsulin resistance into the definition. These investigators
erformed a multivariate analysis that adjusted for age,
ender, and the presence of each of the components of the
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Clinical Trials Group and ‡Office of Biostatistics Research, Nationalpeart, Lung, and Blood Institute, Bethesda, Maryland.etabolic syndrome. Even after adjustment, the diagnosis
f metabolic syndrome was associated with a significant
hreefold increase in risk of coronary heart disease and
troke and a highly significant increase in risk of cardiovas-
ular mortality.
Salonen (7) and Lakka et al. (8) investigated the inde-
endent prognostic impact of a diagnosis of metabolic
yndrome in patients entered into the Kuopio Ischemic
eart Disease Risk Factor Study. This is a prospective
opulation-based study of men living in eastern Finland.
akka et al. (8) excluded men with a history of cardiovas-
ular disease, cancer, or diabetes at baseline. Multivariate
nalysis was performed using the NCEP and also the WHO
riteria for the diagnosis of the metabolic syndrome. With
ither definition, presence of the metabolic syndrome was
ssociated with increased risk independent of known covari-
tes, including the presence of the components of the
etabolic syndrome.
The study of Scuteri et al. (9) reported in this issue of the
ournal adds further data suggestive of synergy among the
isk factors comprising the metabolic syndrome. These
nvestigators studied the effect of the presence of the
etabolic syndrome, according to NCEP criteria, on arte-
ial stiffness in patients entered into the Baltimore Longi-
udinal Study on Aging. Increasing arterial stiffness, for
hich pulse pressure has been a frequently used surrogate, is
trongly associated with adverse cardiovascular events (10–
7). Arterial stiffness tends to increase with normal aging
nd to be accelerated by the presence of cardiovascular risk
actors in a manner that depends on their duration, severity,
nd interaction (10). In a sense, arterial stiffness represents
subtle integration of coronary risk factors into a single
uantity.
Scuteri et al. (9) examined 471 participants, determining
arotid intimal-medial thickness and arterial stiffness. Re-
ression modeling disclosed a strong association of the
resence of metabolic syndrome, by NCEP criteria, with
ncreased arterial stiffness and carotid intimal-medial thick-
ess that was independent of cardiovascular risk covariates,
ncluding each of the components of the metabolic syn-
rome. Furthermore, higher order interaction terms were
lso associated with increased stiffness and carotid-intimal
hickening, suggesting synergy among the risk factors.
Thus, the available data suggest that that the confluence
f risk factors that comprise the metabolic syndrome have a
ynergistic negative impact on prognosis. An effective ther-
peutic (including preventive) attack on the metabolic
yndrome could dramatically reduce the burden of cardio-
ascular disease, underscoring the need for a far more
omplete understanding of the syndrome.
Central to progress is determining how to best define the
etabolic syndrome. The NCEP definition is easily ascer-
ainable by physicians and is therefore convenient opera-
ionally. However, are all of the components that should be
art of the syndrome present and are they optimally de-
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April 21, 2004:1396–8 Editorial Commentned? For instance, a central feature of the metabolic
yndrome is insulin resistance (18). However, fasting hy-
erglycemia is an insensitive measure of insulin resistance
19). Insulin resistance may be present before the develop-
ent of overt diabetes (20), and its early detection might
dentify patients for therapy aimed at preventing the devel-
pment of diabetes. Approaches to early prevention might
enefit from including an assessment of insulin resistance
uch as that incorporated in the WHO definition [highest
uartile of: (plasma glucose  plasma insulin)/22.5] (3,6).
Another example of the difficulty with finding the opti-
al definition of metabolic syndrome components is obe-
ity. The NECP criterion is easily ascertained, but is it the
est possible estimate of obesity? Adipose tissue secretes a
ariety of potentially atherosclerosis-inducing compounds,
he adipocytokines (4). It has been suggested that the level
f these compounds may be a better predictor of outcome
han simple waist circumference (4).
Clearly, a balance is needed between feasibility of ascer-
ainment and prognostic effectiveness. Perhaps the defini-
ion of metabolic syndrome should be expanded in a way
hat permits more diagnostic flexibility in settings where the
asily ascertained components of the NCEP definition are
ot present. One size simply may not fit all. For instance,
nsulin resistance precedes the development of fasting hy-
erglycemia. It is at this stage that the recognition of the
resence of the metabolic syndrome might prompt preven-
ive treatment rather than waiting for the development of
vert diabetes. An approach to population screening may
equire coarser, but more easily ascertainable, measures to be
ractical than the more detailed workup available in a clinic
evoted to lipid disorders.
Another important question is what elements should
e present in the definition of the metabolic syndrome.
ertainly, the elements that synergistically increase risk
nd/or risk factors that share a common etiology should
e incorporated. Additionally, markers in the pathophys-
ological pathway that result in the development of
etabolic syndrome components may be useful additions.
or instance, it has been demonstrated that inflammatory
arkers, such as C-reactive protein, are associated with
ncreased CVD risk independent of the metabolic syn-
rome (18). Data suggesting that inflammation may be a
ause of diabetes raise the possibility that inflammation
ay important as an underlying etiology of the metabolic
yndrome (4,16). The incorporation of inflammatory
arkers may, therefore, be a useful addition to the
efinition of metabolic syndrome.
Careful definition of the metabolic syndrome will lead to
ore effective prevention and treatment strategies. Addi-
ionally, an improved understanding of the dose–response
elationship of risk factor reduction to prognosis is needed
o formulate more effective treatment guidelines.
onclusions. The metabolic syndrome is a series of syn-
rgistically interacting risk factors for CVD, many or all of
hich may share a common etiology, at least in a substantialroportion of patients. A better understanding of how to
est define this syndrome is needed, including what com-
onents should be part of the definition and how they
hould be measured. Also, delineation of the etiology of the
yndrome, including heterogeneity of etiology, will be useful
n refining prevention and treatment strategies. The daunt-
ng dimensions of the apparent risk factor epidemic repre-
ented by the metabolic syndrome, combined with the
uggestion that effective prevention and treatment para-
igms are likely possible, strongly motivates research on this
ntity.
eprint requests and correspondence: Dr. Michael Domanski,
linical Trials Group, National Heart, Lung, and Blood Institute,
701 Rockledge Drive, Room 8146, Bethesda, Maryland 20892.
-mail: domanskm@nih.gov.
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